An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
For more information about the trial above please contact the study team:
Principal Investigator, Irl Greenwell, at firstname.lastname@example.org, or please call +1 843-792-4759.
Study Coordinator, Sarah Milligan, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina